Danaher Corporation (DHR): financials, SEC filings and peers

Danaher Corporation (DHR) is a life sciences tools & services company in the Health Care sector of the S&P 500, headquartered in Washington, D.C..

It was founded in 1969 and joined the S&P 500 on November 18, 1998.

Its fiscal year ends in December, and its shares trade on the NYSE.

In its SEC filings it is classified as “Industrial Instruments For Measurement, Display, and Control”.

Danaher Corporation at a glance

Revenue (12 months): $25.1B
Revenue growth: +4.6%
Operating margin: 20.4%
Net income (12 months): $4.0B
Free cash flow (12 months): $5.5B
Cash: $4.3B
Debt: $26.6B
Diluted EPS (12 months): $5.63

Twelve months to June 26, 2026, from the 10-Q filed July 21, 2026.

Latest twelve months

Over the twelve months to June 26, 2026, Danaher Corporation reported revenue of $25.1 billion, about the same as a year earlier (+4.6%).

Its operating margin was 20.4%, up 2.0 percentage points from a year earlier: for every $100 of sales, about $20 was left as operating profit.

Net income was $4.0 billion (15.9% of revenue), 17.3% higher than a year earlier.

Operating cash flow was $6.6 billion and capital spending $1.2 billion, leaving free cash flow of $5.5 billion (21.8% of revenue).

At the end of the period it held $4.3 billion in cash and $26.6 billion in debt, a net debt position of $22.2 billion.

The diluted share count fell 1.6% in a year, typically the result of buybacks.

Five-year trend

Revenue went from $22.3 billion in fiscal 2020 to $24.6 billion in fiscal 2025, about 2.0% a year.
Operating margin has been steady, around 19.1%.
Free cash flow was positive in each of the last 6 fiscal years.

Fiscal year	2021	2022	2023	2024	2025
Revenue	$24.8B	$26.6B	$23.9B	$23.9B	$24.6B
Revenue growth	11.3%	7.4%	-10.3%	-0.1%	2.9%
Operating margin	25.7%	28.3%	21.8%	20.4%	19.1%
Net income	$6.4B	$7.2B	$4.8B	$3.9B	$3.6B
Free cash flow	$7.1B	$7.4B	$5.8B	$5.3B	$5.3B
Diluted EPS	$8.61	$9.66	$6.38	$5.29	$5.05

Fiscal years as reported in Danaher Corporation’s 10-K filings. Free cash flow is operating cash flow minus capital spending.

Recent SEC filings

8-K filed August 3, 2026 — Executive or director change; Regulation FD disclosure
8-K filed July 21, 2026 — Earnings results
10-Q filed July 21, 2026 — quarterly report
8-K filed June 3, 2026 — New debt obligation; Other event
8-K filed May 7, 2026 — Executive or director change; Shareholder vote results
8-K filed April 29, 2026 — Material agreement; Other event
8-K filed April 21, 2026 — Earnings results
10-Q filed April 21, 2026 — quarterly report

All Danaher Corporation filings on SEC EDGAR

Companies like Danaher Corporation

Other S&P 500 companies in Life Sciences Tools & Services:

More from Health Care

All 60 Health Care companies →

Questions about Danaher Corporation

Is Danaher Corporation's revenue growing?

Yes. Revenue for the twelve months to June 26, 2026 was $25.1 billion, up 4.6% from a year earlier, according to its SEC filings.

Is Danaher Corporation profitable?

Yes. It earned $4.0 billion in net income over the twelve months to June 26, 2026, a net margin of 15.9%.

Does Danaher Corporation have more cash or more debt?

At June 26, 2026 it had $4.3 billion in cash and $26.6 billion in debt, so more debt than cash.

When did Danaher Corporation last file financial results?

Its latest quarterly report (10-Q) was filed with the SEC on July 21, 2026.

Which companies are similar to Danaher Corporation?

In the S&P 500, Danaher Corporation is grouped in Life Sciences Tools & Services within the Health Care sector. Agilent Technologies (A), Charles River Laboratories (CRL), Illumina, Inc. (ILMN), IQVIA (IQV), Mettler Toledo (MTD) are in the same group.

Understand the numbers

Source: Danaher Corporation’s filings with the U.S. Securities and Exchange Commission (EDGAR), retrieved September 27, 2026. Figures are as reported by the company and may be restated. This page is for information only and is not financial advice.